More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Montreal, Quebec--(Newsfile Corp. - September 9, 2025) - Manganese X Energy Corp. (MN:CA) (FSE: 9SC) (TRADEGATE: 9SC) (OTCQB: MNXXF) ("Manganese X" or the "Company") is pleased to announce it is ...

Lorna Ewart has long been frustrated by the mismatch between animal and human toxicity data. All too often preclinical studies in rats and dogs will suggest a drug is safe, only for clinical trial ...